Rita Numerof, Contributor

The plan is a rehash of a years-old idea to require pharmaceutical companies to “negotiate” prices with Medicare officials. This plan is dramatic and — if passed — will have devastating implications for an industry which has been a crown jewel of U.S….

In situations like these, cool rationality and optimism are needed more than ever. In the face of ambiguous situations, we should resist the temptation to craft a negative spin that will drive attention or support a certain agenda.

By its own admission, CMS has acknowledged that the last 10 years of experimentation haven’t worked. Coaxing people – and by extension organizations – to assume more accountability for outcomes hasn’t worked in the past, and it won’t work in the future…

The reality is that you can’t convince all people all the time to do anything in particular, and you certainly can’t convince people who aren’t already pre-disposed to believe certain ‘facts’ to accept them on someone’s say-so. It’s here that credibili…

One dollar may sound awfully cheap for an entire hospital, but when you consider how hard a safety net hospital’s business model is; how much time, money and energy will need to be invested to prevent history from repeating itself; this shouldn’t come …

The basis for the “science” of 6 feet of distance is rooted in work done with tuberculosis in the late 19th century, not on current scientific inquiry. Presenting it as a “fact” that applies to a current situation has been greatly misleading.

It is true that the CARES Act’s Provider Relief Fund did help hospitals all across the country stay afloat. However, as earnings reports reveal, not all hospitals and health systems are financially struggling nearly as badly as people thought they woul…

Considering how much hospital margins have shrunk in the last year because of Covid-19, if commercial reimbursement rates were to right now become government controlled even at 150% of government rates, that could cause either massive bankruptcies or m…

Individuals at Amazon – who weren’t necessarily Bezos – have been making systematic investments in healthcare-related businesses for years. And those investments won’t be automatically undone just because a new CEO is stepping in.

Drug manufacturers’ decades old commercial model – which initially depended on manufacturers having a plethora of “feet in the street” and ample face-to-face, in-person interactions with physicians – was in jeopardy long before the pandemic began. Covi…